HSK39297 clinical trials
Also written HSK39297.
How each study uses HSK39297 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HSK39297 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test HSK39297.
- Dec 2026A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA NephropathyPhase 2 · Haisco Pharmaceutical Group Co., Ltd.
- Jun 2027Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal HemoglobinuriaPhase 2 · Haisco Pharmaceutical Group Co., Ltd.
- Nov 2027Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNPhase 2 · Haisco Pharmaceutical Group Co., Ltd.
Studies
Open first, then newest update. How each study uses HSK39297 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA NephropathyRecruitingPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT07616700Written as HSK39297 200mgQD
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANRecruitingPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT07390123Written as HSK39297
- Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNRecruitingPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT07363460Written as HSK39297 200mgQD
- Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic ImpairmentRecruitingPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT07152288Written as HSK39297 tablets
- Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal HemoglobinuriaRecruitingPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT06745622Written as HSK39297 tablets
- Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANCompletedPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT06670352Written as HSK39297 50mgBID
- Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With AnemiaCompletedPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT07052838Written as HSK39297 tablets
- A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor TherapyCompletedPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT06799546Written as HSK39297 tablets
- A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria(PNH)CompletedPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT06561841Written as HSK39297
- A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy SubjectsCompletedPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT06350279Written as HSK39297